Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
World J Clin Oncol
2011 Nov 10;211:362-6. doi: 10.5306/wjco.v2.i11.362.
Show Gene links
Show Anatomy links
Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata.
Sima P
,
Vetvicka V
.
???displayArticle.abstract???
The marine environment provides a rich source of natural products with potential therapeutic application. This has resulted in an increased rate of pharmaceutical agents being discovered in marine animals, particularly invertebrates. Our objective is to summarize the most promising compounds which have the best potential and may lead to use in clinical practice, show their biological activities and highlight the compounds currently being tested in clinical trials. In this paper, we focused on Bryozoa, Mollusca, Echinodermata and Urochordata.
Amador,
Progress in the development and acquisition of anticancer agents from marine sources.
2003, Pubmed
Amador,
Progress in the development and acquisition of anticancer agents from marine sources.
2003,
Pubmed
Baunbaek,
Anticancer alkaloid lamellarins inhibit protein kinases.
2008,
Pubmed
Beckwith,
Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
1993,
Pubmed
Blackhall,
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
2001,
Pubmed
Charupant,
Jorunnamycins A-C, new stabilized renieramycin-type bistetrahydroisoquinolines isolated from the Thai nudibranch Jorunna funebris.
2007,
Pubmed
Diyabalanage,
Palmerolide A, a cytotoxic macrolide from the antarctic tunicate Synoicum adareanum.
2006,
Pubmed
Dorr,
Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
1988,
Pubmed
El-Rayes,
Phase I study of bryostatin 1 and gemcitabine.
2006,
Pubmed
Erba,
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
2001,
Pubmed
Fukuzawa,
Isolation of 13 New Ritterazines from the Tunicate Ritterella tokioka and Chemical Transformation of Ritterazine B(1).
1997,
Pubmed
García-Rocha,
The antitumoral compound Kahalalide F acts on cell lysosomes.
1996,
Pubmed
Grubb,
Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described.
1995,
Pubmed
Guan,
Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata.
1993,
Pubmed
Haldar,
Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells.
1998,
Pubmed
Iijima,
Biopolymers from marine invertebrates. XIV. Antifungal property of Dolabellanin A, a putative self-defense molecule of the sea hare, Dolabella auricularia.
1994,
Pubmed
In,
Molecular conformation of patellamide A, a cytotoxic cyclic peptide from the ascidian Lissoclinum patella, by X-ray crystal analysis.
1993,
Pubmed
Ishida,
Molecular conformation of ascidiacyclamide, a cytotoxic cyclic peptide from Ascidian: X-ray analyses of its free form and solvate crystals.
1992,
Pubmed
Jiang,
Total synthesis and structure revision of the marine metabolite palmerolide A.
2007,
Pubmed
Kraft,
Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.
1986,
Pubmed
Lopanik,
Potent cytotoxins produced by a microbial symbiont protect host larvae from predation.
2004,
Pubmed
López-Antón,
The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway.
2006,
Pubmed
Maki,
The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
1995,
Pubmed
Mayer,
Marine pharmacology in 2000: antitumor and cytotoxic compounds.
2003,
Pubmed
Mayer,
Marine pharmacology in 1999: antitumor and cytotoxic compounds.
2001,
Pubmed
Mohammad,
Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
1995,
Pubmed
Nagle,
Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.
2009,
Pubmed
,
Echinobase
Peterson,
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
2006,
Pubmed
Pettit,
Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
1995,
Pubmed
Pettit,
Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications.
1998,
Pubmed
Pettit,
Isolation and structure of the cytostatic lignan glycoside phyllanthostatin A.
1988,
Pubmed
Quesada,
Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein.
1996,
Pubmed
Rinehart,
Antitumor compounds from tunicates.
2000,
Pubmed
Sakai,
Structure--activity relationships of the didemnins.
1996,
Pubmed
Sharkis,
The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.
1990,
Pubmed
Vera,
Natural products as probes of cell biology: 20 years of didemnin research.
2002,
Pubmed
Wang,
Oyster (Crassostrea gigas) hydrolysates produced on a plant scale have antitumor activity and immunostimulating effects in BALB/c mice.
2010,
Pubmed
Watters,
Toxins from ascidians.
1993,
Pubmed
Wender,
The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.
1999,
Pubmed
Yamada,
Aplyronine A, a potent antitumour macrolide of marine origin, and the congeners aplyronines B-H: chemistry and biology.
2009,
Pubmed
Yamada,
Cytotoxic substances from two species of Japanese sea hares: chemistry and bioactivity.
2010,
Pubmed
Yao,
The pterocellins, novel bioactive alkaloids from the marine bryozoan Pterocella vesiculosa.
2003,
Pubmed
Zhang,
Secondary metabolites from the South China Sea invertebrates: chemistry and biological activity.
2006,
Pubmed
van Kesteren,
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
2000,
Pubmed
